Cargando…
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
INTRODUCTION: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular complications. Because of the progressive pathophysiology of T2DM, oral antidiabe...
Autores principales: | Kulasa, Kristen, Edelman, Steven |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963920/ https://www.ncbi.nlm.nih.gov/pubmed/21042540 |
Ejemplares similares
-
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012) -
Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010) -
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011) -
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Profit, Louise, et al.
Publicado: (2008) -
Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)